IP Library Granted Patent US 9,090,657
Granted Patent B2
US 9,090,657 · App. 13/433,944 · Granted Jul 28, 2015

Compound and methods for its production

Inventors: Matthew Alan Gregory (Cambridge, GB); Steven James Moss (Cambridge, GB); Barrie Wilkinson (Cambridge, GB)
Assignee: NEUROVIVE PHARMACEUTICAL AB
C07K5/06078A61K38/06C07D498/04C07D498/06C07K5/06191C07K5/0808
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,657
App. No.
13/433,944
Granted
Jul 28, 2015
Kind
B2
Abstract

There is provided inter alia a compound of formula (I): for use in treatment of viral infection or as an immunosuppressant.

Claims (12)

1. A compound of formula (I):

including any tautomer thereof; or an isomer thereof in which the C26, 27 C═C bond shown as trans is cis; and including a methanol adduct thereof in which a ketal is formed by the combination of the C-53 keto (if present) and the C-15 hydroxyl group and methanol;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 is solid crystalline form.

3. A compound according to claim 2 in the form of its Form I crystalline polymorph.

4. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable diluent or carrier.

5. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable diluent or carrier further comprising a second or subsequent active ingredient.

6. A method of treating an HCV, HBV, or HIV infection, which comprises administering to a subject a therapeutically effective amount of a compound according to claim 1 .

7. A process for preparing a compound according to claim 1 which comprises reacting a compound of formula (V)

wherein each R 11 is independently C 1-4 alkyl or benzyl;

with an aldehydic macrocycle (compound of formula VI):

8. A process for the preparation of a compound of formula (I) in the form of its Form I crystalline polymorph according to claim 3 comprising the step of crystallising a compound of formula (I) from methyl isobutyl ketone.

Assignments (3)
CHANGE OF NAME Recorded Oct 15, 2020
From: NEUROVIVE PHARMACEUTICAL AB
To: ABLIVA AB
Reel/Frame 054088/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: BIOTICA TECHNOLOGY LIMITED (IN CREDITORS VOLUNTARY LIQUIDATION)
To: NEUROVIVE PHARMACEUTICAL AB
Reel/Frame 032404/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2012
From: MOSS, STEVEN JAMES; GREGORY, MATTHEW ALAN; WILKINSON, BARRIE
To: BIOTICA TECHNOLOGY LTD.
Reel/Frame 027955/0306 →
Priority Claims (3)
GB 1105293.3 · Mar 29, 2011 · national
GB 1113629.8 · Aug 8, 2011 · national
GB 1202060.8 · Feb 7, 2012 · national
Continuity (1)
Related Publication 20120251581A1 · Oct 4, 2012